Tag Archives: Johnson & Johnson
By Pharm Exec | Published: November 19, 2014
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to GlobalData.
By Pharm Exec | Published: November 14, 2014
Johnson & Johnson completed the acquisition of Alios BioPharma, a privately held clinical-stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash. Alios BioPharma will become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson. The acquisition […]
By Pharm Exec | Published: March 25, 2014
The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) — at the time the first TB drug approval in 40 years — “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
By Clark Herman | Published: October 30, 2013
At last week’s 4th annual Prix Galien Forum hosted by the Alexandria Center in New York, industry leaders gathered to discuss trends and developments that shape the intersection between science and policy. The centerpiece of the day was a panel on US health reform – focused on rollout of the Affordable Care Act — featuring […]
By Guest Blogger | Published: July 31, 2013
by Mike Kelly and Andrew Dupre Insurance contracts are a language game that must be played very carefully, as AstraZeneca learned. From 2003 to 2012, AstraZeneca Plc was locked in one of the largest mass tort litigations in the United States, defending its blockbuster second generation atypical antipsychotic product Seroquel from allegations of failure-to-warn of […]